...Avid scientists' ability to characterize and reverse engineer another company’s protein drug (the skills required to be a serious player in FoB’s). Talk is cheap.
We PPHM shareholders expect news on the Avid Biosimilars front after Labor Day and the short time until then is not worth belaboring. Just what the heck is it to you, why do you care?
Market Data 
Markets 
AI
